Clinical Trial Update: Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nab-paclitaxel plus S-1 as first-line therapy for advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Aiping Zhou | Conditions: Advanced Pancreatic Cancer | Phase 2 | Status: COMPLETED